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Dimethylarginine dimethylaminohydrolase I enhances tumour
growth and angiogenesis
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Angiogenesis is a prerequisite for tumour progression and is highly regulated by growth factors and cytokines a number of
which also stimulate the production of nitric oxide. Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide
synthesis. Asymmetric dimethylarginine is metabolised by dimethylarginine dimethylaminohydrolase. To study the effect of
dimethylarginine dimethylaminohydrolase on tumour growth and vascular development, the rat C6 glioma cell line was
manipulated to overexpress the rat gene for dimethylarginine dimethylaminohydrolase I. Enhanced expression of
dimethylarginine dimethylaminohydrolase I increased nitric oxide synthesis (as indicated by a two-fold increase in the
production of cGMP), expression and secretion of vascular endothelial cell growth factor, and induced angiogenesis in vitro.
Tumours derived from these cells grew more rapidly in vivo than cells with normal dimethylarginine dimethylaminohydrolase I
expression. Immunohistochemical and magnetic resonance imaging measurements were consistent with increased tumour
vascular development. Furthermore, dimethylarginine dimethylaminohydrolase activity was detected in a series of human
tumours. This data demonstrates that dimethylarginine dimethylaminohydrolase plays a pivotal role in tumour growth and the
development of the tumour vasculature by regulating the concentration of nitric oxide and altering vascular endothelial cell
growth factor production.
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Angiogenesis is the formation of new capillaries from existing
blood vessels. It is a multistep process that involves dissociation
of endothelial cells (EC) from adjacent pericytes, remodelling of
the extracellular matrix, proliferation and migration of EC and
capillary differentiation. Insight into the regulation of this process
is central to our understanding of a number of biological processes
whether physiological, as occurs during development, the repro-
ductive cycle and wound healing, or pathological, as occurs
during atherogenesis, diabetic retinopathy and tumour progression
(Carmeliet and Jain, 2000; Folkman, 1995).
There is strong evidence to suggest that nitric oxide (NO),
produced from arginine by the nitric oxide synthases (NOS), is a
crucial signalling molecule and regulator of angiogenesis (Chinje
and Stratford, 1997). NO enhances vascular permeability, induces
extracellular matrix degradation, endothelial cell proliferation and
migration (Ziche et al, 1994; Trachtman et al, 1996; Fukumura et
al, 1997) and stimulates the expression of vascular endothelial
growth factor (VEGF) while also mediating many of its angiogenic
effects (Chin et al, 1997; Papapetropoulos et al, 1997). The role of
NO in tumour progression is still unclear, since NO has been
shown to inhibit angiogenesis (Pipili-Synetos et al, 1995) and
NO produced by activated macrophages can be cytotoxic to
tumour cells (Stuehr and Nathan, 1989). However, NO has been
positively correlated with tumour grade in human gynaecological,
breast, neuronal, and head and neck tumours (Thomsen et al,
1994; Cobbs et al, 1995; Gallo et al, 1998; Reveneau et al, 1999).
Regulation of NO production may therefore play an important
role in the regulation of angiogenesis and consequently tumour
progression. Methylated analogues of arginine such as asymmetric
dimethylarginine (ADMA) and N-mono methylarginine
(L-NMMA) are competitive inhibitors of NO synthesis. Free
ADMA is found in plasma and urine of healthy individuals and
is synthesised by the post-translational methylation of protein argi-
nine residues and liberated upon their hydrolysis (Kakimoto and
Akazawa, 1970; Fickling et al, 1993). The intracellular concentra-
tion of ADMA reaches levels sufficient to inhibit NO synthesis
(Macallister et al, 1994) and can be modulated by changes in the
activity of the enzyme dimethylarginine dimethylaminohydrolase
(DDAH) (Ogawa et al, 1989; Macallister et al, 1996).
Two isoforms of DDAH have been reported (Leiper et al, 1999).
DDAH I predominates in tissues that express the neuronal isoform
of NOS, while DDAH II distribution mainly follows endothelial
NOS (Leiper et al, 1999). Dysfunction of DDAH and elevated levels
of its substrate ADMA have been implicated in pathological condi-
tions including hypertension, pre-eclampsia, renal failure and
atherosclerosis (Matsuoka et al, 1997; Holden et al, 1998; Miyazaki
et al, 1999). Recently, high levels of ADMA have been correlated
with impaired angiogenesis in hypercholesterolemic mice (Jang et
al, 2000). The aim of our study was to test the hypothesis that
tumour-derived ADMA plays a significant role in the regulation
of tumour growth and vascular development. We demonstrate that
increased DDAH expression results in decreased tumour ADMA,
increased NO production, tumour growth and angiogenesis, and
that these effects are mediated through changes in the expression
of VEGF. We also show preliminary evidence of DDAH activity
in human tumours.
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METHODS
Cell culture and transfections
Rat C6 glioma cells (European Collection of Cell Cultures, Centre
for Applied Microbiology and Research, UK) were maintained in
Ham’s F-10 medium containing 5 mM L-glutamine, 100 U ml71
penicillin, 0.1 mg ml71 streptomycin and 10% (v v71) foetal calf
serum. The full length rat DDAH I cDNA was generated by
RT – PCR using mRNA isolated from C6 cells, forward primer:
GGAGCAAGCTTCGCCACCATGGCCGGCCTCAGCCA and reverse
primer: GCCTGCTCGAGTCAAGAGTCTGTCTTCTTGTTAAT and
subsequently cloned into HindIII/XhoI sites in pcDNA 3.1/hygro
(InVitrogen). C6 cells were transfected using the poly L-ornithine
method (56106 cells per 9 cm plate; 10 mg DNA plasmid;
10 mg ml71 poly L-ornithine) and selected in medium supplemen-
ted with 500 mg ml71 hygromycin B (Dong et al, 1994).
Animals and tumours
Female (7 – 8 weeks old) MF1/nu mice were injected subcuta-
neously in the flanks with 26106 cells in 0.1 ml PBS. Tumour
growth was measured at daily intervals after anaesthetising with
fluothane in 2% N2O, 5% O2. The tumour volume was calculated
using the formula: tumour volume=p/6×(length6width6depth).
All procedures were performed in accordance to the Home Office
Scientific Procedures Act 1986.
Western blot analysis
The protein concentration of cell lysates and tumour homogenates
were determined by Bradford assay and equal amounts analysed by
SDS – PAGE. DDAH expression was detected using a monoclonal
antibody against rat DDAH I (Kimoto et al, 1995).
DDAH activity assay
Cells were seeded on 24-well plates at a density of 1.56105 cells
per well and incubated in HEPES buffered Krebs solution contain-
ing [14C] L-NMMA (0.8 mCi ml71, specific activity 56 mCi
mMol71) for 1 h at 378C. Cells were washed twice in ice-cold
Krebs solution and lysed in 0.1% (w v71) SDS. Human tumour
biopsy specimens taken during surgical removal of the tumour,
or mouse tumour tissues were homogenised in 10 mM sodium
phosphate buffer pH 6.6 using a motor homogeniser. Aliquots of
500 ml were incubated with [14C] L-NMMA (0.4 mCi ml71) for
1 h at 378C. The formation of [14C] citrulline was determined as
previously described (MacAllister et al, 1996). The enzymatic activ-
ity was corrected for the protein concentration.
HPLC analysis
Assessment of the concentration of ADMA in tumour homogenates
and in culture medium was performed as previously described
(MacAllister et al, 1994).
cGMP assay
Estimation of the production of cGMP in tumour cells was
performed as previously described (Whitley, 1994).
In vitro assay of endothelial cell migration
A human endothelial cell line SGHEC-7 derived from SV40 trans-
fected human umbilical vein endothelial cells (Fickling et al, 1992)
was cultivated on microcarrier (MC) beads for 2 days and embedded
in fibrin gels (Nehls and Drenckhahn, 1995). Conditioned medium
from confluent cultures mixed 1 : 1 with fresh medium was added.
After 2 days incubation, digital images were acquired and the extent
of migration was determined using Image Pro-Plus software (Media
Cybernetics). Invasion was determined as the maximum length of
invasive processes minus the radius of the bead.
Northern blot analysis
Total RNA was prepared from cells using TRIZOL (Gibco BRL).
The probe for VEGF was a 540 bp BamHI-HindIII fragment of
the human VEGF121 cDNA (nt 565 – 1012). The high identity in
the cDNA sequences of human and rat or mouse VEGF ensures
the crossreactivity of the probe (Shima et al, 1996). The probe
for the 18S subunit corresponds to nucleotides 552 – 1429 nt of
the human 18S gene.
VEGF ELISA
Culture medium was collected from confluent 6-well plates and
analysed for VEGF expression using a murine VEGF ELISA kit
(R&D Systems, detection limit 3 pg ml71). Tumours were excised
at an early stage of development (day 15), weighed, cut in small
pieces and maintained in culture medium for 4 days. VEGF secre-
tion was measured in the culture medium. Values were correlated
with the protein concentration of cells or the weight of tumours,
respectively.
Magnetic resonance imaging (MRI)
A separate cohort of size-matched D27 and C6 wild type tumours
were imaged at 18 and 23 days post-passage respectively. 1H MR
imaging was performed on a Varian spectrometer at 4.7 T using
a two-turn surface coil (1 cm diameter). Mice bearing tumours
derived from D27 (mean volume 1.23+0.2 cm3, n=8) or C6 (mean
volume 1.25+0.2 cm3, n=8) wild type cells were anaesthetised with
a single intraperitonal dose of 10 ml kg71 Hypnorm/Hypnovel and
placed so the tumour hung into the centre of the surface coil. The
mouse core temperature was maintained at 378C by a warm water
blanket. Multi-gradient echo (MGRE) images were acquired from
three transverse 1 mm thick slices through the centre of the
tumour. The readout gradient was oscillated to generate a series
of eight echoes, utilising a repetition time of 100 ms, initial echo
of 5 ms and an echo spacing of 5 ms, resulting in sets of images
with decreased R2* weighting. Tumour R2* maps for each slice
were generated using all eight gradient-echo image sets by fitting
an exponential model on a pixel-by-pixel basis (Robinson et al,
2001; Griffiths et al, 2002). For each slice, R2* was determined
from a region-of-interest (ROI) encompassing the whole tumour
but excluding the surrounding skin/muscle.
Fluorescence microscopy
Mice from the same cohort as used for the MRI and bearing simi-
larly size-matched tumours were injected intravenously with
15 mg kg71 of the perfusion marker Hoechst 33342 (Sigma)
1 min prior to cervical dislocation. Tumours were rapidly excised,
frozen and sections cut (10 mm). Acetone fixed sections were visua-
lised by fluorescence microscopy. Fluorescence signals from entire
tumour sections were recorded with digital images acquired under
identical conditions. The area of tumour stained by Hoechst 33342
as a percentage of the total area of tumour section was calculated
using anaLYSIS (Soft Image Analysis).
Ethics
Local Ethical Committee approval was obtained for the collection
of human tissues.
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RESULTS
Overexpression DDAH in C6 glioma cells
To study the role of DDAH in tumour biology, the rat C6 glioma
cell line was transfected with the pcDNA vector, containing the
coding region of the rat DDAH I gene. Three stable clones,
(D20, D26, D27) that constitutively express DDAH I and mock
transfected clones (M lines, transfected with the empty vector as
control) were analysed. Western blot analysis of D20, D26 and
D27 cells revealed similarly high levels of DDAH I protein expres-
sion (Figure 1A). Consistent with the high protein expression these
cell lines displayed, on average, a four-fold increase in enzymatic
activity compared to wild type C6 and control transfected M4 cells,
as determined by the conversion of 14C radiolabelled L-NMMA to
L-citrulline (Figure 1B). Since the function of DDAH is to catabo-
lise the endogenous inhibitors of NO, ADMA and L-NMMA, the
levels of ADMA in the culture medium of the overexpressing cell
lines was examined. Overexpression of DDAH I was shown to
reduce the levels of ADMA by 70 – 75% (Figure 1C). Consistent
with the role of ADMA as an inhibitor of NO, the decreased levels
of ADMA led to an increase in NO production as indicated by a
two-fold increase in the production of cGMP (C6: 12.33+1.4,
D27: 26.67+1.5, mean+s.e.mean). In vitro studies showed no
apparent correlation between transfection with DDAH (compared
to empty vector) and growth (Figure 1D). However transfected
cells generally showed slower growth rates than C6 wild type cells.
All three DDAH I overexpressing cell lines grew similarly to M4
and M6 (Figure 1D) and other mock transfected lines (data not
shown).
Effect of DDAH I overexpression on tumour growth in vivo
In contrast, when D26 and D27 cells were implanted into the
flanks of nude mice their growth rate increased (doubling time:
*2 days) compared to the wild type or the control M4 cells
(doubling time: *4 days, Figure 2A). In a limited number of
experiments the growth of C6 tumours was allowed to continue
until day 26 when they reached a similar size to that of D27 at
20 days (data not shown). Western blot analysis of tumours
demonstrated higher DDAH I protein expression in D27 compared
to C6 tumours (Figure 2B). Homogenates from D26 and D27
tumours displayed a 2.5-fold increase in DDAH activity (Figure
2C). The concentration of ADMA also decreased from
2.6 mg mg71 protein in C6 tumours to undetectable levels in
D27 tumours.
Effect of DDAH I on tumour vascular development
Non-invasive Magnetic Resonance Imaging (MRI) was employed
to assess the blood vessel development in vivo. Deoxyhaemoglobin
is paramagnetic and creates magnetic susceptibility perturbations
around blood vessels, increasing the MRI transverse relaxation time
R2*. Multi-gradient recalled echo (MGRE) MR images allow the
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Figure 1 Characterisation of the stable DDAH I transfected cell lines in
vitro. (A) Western blot analysis of DDAH I overexpressing cell lines (20 mg
protein per lane). An increase in a band at approximately 38 kDa, indicating
the presence of DDAH I was observed. (B) Assessment of DDAH activity
in cell lysates by the conversion of [14C] L-NMMA to L-citrulline revealed
that the D20, D26 and D27 cell lines had a four-fold increase in DDAH
enzymatic activity. Results are means+s.e.m. of triplicates of three separate
experiments (***P50.001 compared to control, Student’s t-test). (C)
Overexpression of DDAH I reduced the concentration of ADMA by
70 – 75% in the culture medium as determined by HPLC analysis. Results
are mean %+s.e.m. of triplicate determinations from three separate experi-
ments (***P50.001, Student’s t-test). (D) The in vitro growth rate of
DDAH transfected cells (dashed lines) D20, D26, D27, mock transfected
cells (solid lines) M4, M6 and wild type C6 cells is shown. Results are
means+s.e.m. of three experiments performed in at least duplicate.
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relaxation rate R2* to be quantified, which is directly proportional
to the tissue content of deoxyhaemoglobin and hence a sensitive
index of tissue vascularity (Robinson et al, 2001; Griffiths et al,
2002). The average R2* of D27 and C6 tumours was 65.6+5 s
71
and 42.5+4 s71 respectively. The significantly faster R2* displayed
by the D27 tumours compared to the wild type (Student’s t-test,
P50.001) indicates a higher concentration of deoxyhaemoglobin
and increased tumour vascularisation (Figure 3A). In addition to
the higher growth rate, tumours derived from the D27 cells were
shown upon excision to bleed profusely and to be more vascu-
larised compared to wild type tumours (Figure 3B).
DDAH I expression results in increased tumour perfusion
The effect of DDAH I on tumour perfusion was examined using
the fluorescent marker Hoechst 33342 (Smith et al, 1988). This
is a nuclear dye that, upon injection, stains endothelial cells and
cells immediately adjacent to tumour blood vessels. Since the time
of experiment was limited to 1 min to avoid diffusion of the dye,
Hoechst 33342 marked only the functionally perfused vessels.
Fluorescence microscopy showed that the extent of the staining
is greater in D27 tumours compared to wild type tumours indicat-
ing better tumour perfusion and increased number of functional
vessels (C6: 5.1%+0.5, D27: 9%+0.5, mean+s.e.m, n=4).
DDAH I induces in vitro vascular endothelial cell
migration
The role of DDAH I on vessel development was examined further
using an in vitro assay of endothelial migration. Human endothelial
cells, SGHEC-7, grown on microcarrier (MC) beads and embedded
in fibrin gels were incubated with conditioned medium from
confluent cultures of C6, D27 or SGHEC-7 cells and the formation
of invasive processes was analysed over a period of 2 days. Invasion
of endothelial cells into the fibrin gel was used as an indicator of
the angiogenic potential of factors produced by the D27 cells.
The average of the maximum length of the process minus the
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Figure 3 Overexpression of DDAH I affects the tumour vasculature.
(A) Representative R2* maps obtained from size-matched C6 and D27 tu-
mours, and their associated average R2* relaxation rates, imaged 23 days
and 18 days post-passage respectively. The more intense R2* map (brighter
image) of the D27 tumour is consistent with a high concentration of de-
oxyhaemoglobin and hence better vessel development. (B) Representative
photographs of size-matched tumours derived from C6 and D27 cells. C6
and D27 tumours were excised 26 and 20 days post-implantation respec-
tively. DDAH I overexpressing tumours are better vascularised compared
to wild type or control tumours.
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Figure 2 Overexpression of DDAH I increases the in vivo tumour
growth rate. (A) In vivo, overexpression of DDAH I caused an increase
in the growth rate of D20, D26 and D27 tumours compared to M4 and
C6 tumours. Results are means+s.e.m. of at least two different inocula-
tions of six mice. (B) Western blot analysis of tumours (100 mg protein
per lane) confirmed that the overexpressing DDAH tumours had higher
amounts of DDAHI protein in vivo. (C) Assessment of DDAH activity in
tumour homogenates by the conversion of [14C] L-NMMA to L-citrulline.
Tumour homogenates derived from D26 and D27 revealed a two- and
a half-fold increase in their DDAH activity compared to C6 tumours. Re-
sults are means+s.e.m. of duplicates from two separate experiments
(**P50.02 compared to control, Student’s t-test).
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radius of the bead from 40 MC beads was determined. Statistical
analysis showed that conditioned medium from D27 cells signifi-
cantly stimulated the migration of SGHEC-7 cells into the fibrin
gel compared to medium from C6 or SGHEC-7 cells (Figure 4).
DDAH I expression increases the production of VEGF
Since it has previously been suggested that NO can mediate some
of the angiogenic effects of VEGF, we examined whether the effects
of DDAH and ADMA on tumour angiogenesis were mediated
through changes in VEGF. In vitro analysis of VEGF mRNA
displayed a two-fold increase in D20, D26, D27 compared to
control M4 and wild type C6 cells as determined by Northern blot
analysis (Figure 5A). This correlated with an average two-fold
increase in VEGF secretion in the culture medium as determined
by ELISA (Figure 5B). Ex vivo analysis of VEGF secretion displayed
a two-fold increase in D27 compared to C6 tumour culture super-
natant (Figure 5C).
DDAH I activity in human tumours
DDAH activity was detected in eight human tumours, including
those from the brain (Figure 6).
DISCUSSION
Tumour angiogenesis is driven by the requirement of the tumour
for nutrients and oxygen. Angiogenesis involves the coordination
of a number of independent events including the production of
proteases and angiogenic factors that have both a chemotactic
and mitogenic effect on endothelial cells. We demonstrate a novel
mechanism by which a reduction in tumour ADMA, as a result of
increased DDAH activity, stimulates tumour growth and angiogen-
esis through increased NO and VEGF expression.
Regulation of the production of NO through DDAH activity is
important since NO can have pleiotropic effects on diverse aspects
of tumour biology. There is positive correlation between NOS
activity and tumour grade in human breast, gynaecological, head,
neck and neuronal tumours (Thomsen et al, 1994; Cobbs et al,
1995; Gallo et al, 1998; Reveneau et al, 1999) and NOS inhibitors
have been shown to decrease tumour growth (Thomsen et al,
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Figure 5 Overexpression of DDAH I results in upregulation of VEGF.
(A) VEGF mRNA expression in the D27, D26, D20, M4 and parent C6 cell
lines assessed by Northern blot analysis. RNA loading was corrected
according to the levels of the 18S ribosomal subunit. The signal intensity
was quantified by densitometry and expressed as the ratio of VEGF/18S.
The lower panel shows a representative Northern blot analysis of VEGF
expression in cell lysates. (B) VEGF expression in the culture medium of
D27, D26, D20, M4 and parent C6 cell lines assessed by ELISA. Results
are means+s.e.m. of duplicates of three individual experiments
(***P50.001 compared to control, Student’s t-test). (C) VEGF secretion
in the culture medium of D27 and C6 derived tumours were assessed
by ELISA. Results are means+s.e.m. of triplicates of three tumours respec-
tively (***P50.001, Student’s t-test).
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Figure 4 Conditioned medium from DDAH I overexpressing cells in-
duces endothelial cell migration in vitro. A human endothelial cell line
SGHEC-7 was grown on beads in three dimensional fibrin gels and incu-
bated with conditioned medium (cm) from confluent SGHEC-7, D27 or
C6 cells. Quantitative analysis of invasive process formation was expressed
as the average of the maximum length of process minus the radius of
the bead per 40 MC beads. Results are means+s.e.m. of 40 individual
measurements in three separate experiments (***P50.001 compared to
control, Student’s t-test).
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1997). However, the role of tumour-derived NO is still unclear
since overexpression of iNOS in tumour cells can promote or inhi-
bit tumour growth and metastasis (Dong et al, 1994; Jenkins et al,
1995; Xie et al, 1995).
Increased malignancy of human primary brain tumours and the
formation of metastasis is associated with increased neovascularisa-
tion. Astrocytomas represent one of the most vascularised human
neoplasms and the progression from low to high grade is charac-
terised by an increase in neovascularisation, focal necrosis and
cellular proliferation. Tumours derived from the rat C6 glioma cell
line are histologically classified as astrocytomas and represent a
well-established model of human glioblastomas (Barth, 1998). C6
glioma cells express both eNOS and iNOS (Simmons and Murphy,
1993; Barna et al, 1996).
The result of increased DDAH I activity in C6 cells and the
concomitant fall in the concentration of ADMA led to a two-fold
increase in NO synthesis as observed by increased cGMP produc-
tion. However this did not alter the in vitro growth properties of
the glioma cell lines. The in vivo growth rate of D20, D26 and
D27 cells was significantly increased compared to the wild type
or the control M4 cells. Our data suggest that DDAH/ADMA path-
way does not have a direct effect on the cell cycle or cell
proliferation but indirectly affects the tumour growth, possibly
by interfering with the tumour vessel development.
To establish a role for ADMA and DDAH in tumour angiogen-
esis in vivo, MGRE-MRI was used as a non-invasive assay of blood
vessel development of D27 and wild type C6 tumours, followed by
gross histology and fluorescence microscopy using the nuclear dye
Hoechst 33342. It is clear from these experiments that DDAH I
expression leads to higher blood volume, better tumour perfusion
and increased number of functional vessels. We can therefore spec-
ulate that the increased growth observed in D27 tumours is
dependent on increased blood vessel development.
Sprouting of endothelial cells from pre-existing vessels, the inva-
sion into the surrounding tissue and the reorganisation into new
capillary structures are important steps in vessel development.
DDAH I expression and ADMA concentration does not affect
the proliferation rate of endothelial cells (V Kostourou, unpub-
lished observations). Therefore, a possible role of DDAH I in
vessel development could be the facilitation of the endothelial cell
invasion. In support of this, conditioned medium from D27 cells
significantly stimulated the migration of SGHEC-7 cells into the
fibrin gel compared to medium from C6 or SGHEC-7 cells. These
results demonstrate that DDAH activity and the intracellular
concentration of ADMA regulate the release of an angiogenic factor
or factors in vitro that affect the invasive properties of the endothe-
lial cells.
Vessel growth and development is under the control of a
number of factors the most potent being VEGF. VEGF is a largely
endothelial cell-specific mitogen that is induced by hypoxia. It
promotes angiogenesis, blood vessel permeability and maintains
tumour vessel integrity (Shweiki et al, 1992; Yancopoulos et al,
2000). Increased VEGF expression is related to neovascularisation
and tumour progression (Takahashi et al, 1995; Zhang et al,
1995) while inhibition of VEGF or its receptors inhibits tumour
growth in vivo (Kim et al, 1993; Saleh et al, 1996). Since NO
may function as an upstream regulator of expression as well as a
downstream effector of the action of VEGF, we examined whether
the effects of DDAH and ADMA on tumour angiogenesis were
mediated through changes in VEGF. In vitro analysis of VEGF
mRNA production as well as VEGF protein secretion in the culture
medium demonstrated that DDAH I expression stimulates VEGF
production. The increase in VEGF production was similar to that
induced by hypoxia in the same cells (V Kostourou, unpublished
observations).
Our findings indicate that human tumours exhibit DDAH activ-
ity. Although this study is limited in number it does suggest that
human brain tumours express particularly high levels of DDAH
activity. Increased NO production has also been reported in human
CNS tumours (Cobbs et al, 1995). Our experimental data demon-
strates that DDAH I can promote tumour growth and increase
tumour perfusion. Since tumours with a high grade of malignancy
are better perfused and vascularised it is interesting to speculate
that DDAH I could facilitate tumour progression and correlate
with tumour malignancy. The relationship between DDAH activity
and tumour grade is currently under investigation.
In summary, this study shows that increased DDAH expression
results in decreased tumour ADMA, increased NO and VEGF
production, vascularisation and tumour growth. Our results
provide the first demonstration of the importance of the ADMA/
DDAH pathway in the regulation of vessel development. It also
has important implications for the regulation of angiogenesis in
other pathological and physiological circumstances in which VEGF
expression or NO production is involved. The fact that tumour
development is so dramatically altered by regulating this pathway
adds a novel level of complexity to a system where the precise
balance between pro- and anti-angiogenic factors is of key impor-
tance. Therapeutic interventions in oncology using the DDAH/
ADMA pathway are therefore plausible.
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Figure 6 Presence of DDAH activity in human tumours. DDAH activity
in tumour homogenates derived from eight individual human tumour
biopsy specimens taken during surgical removal of the tumour. DDAH
activity was assessed by the conversion of [14C] L-NMMA to L-citrulline.
DDAH activity varied in the different tumour types.
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